Ireland Natalizumab (TYSABRI) Observational Program
NCT01943526 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 191
Last updated 2018-05-04
Summary
The objectives of this study are to assess the long-term safety and impact on disease activity and progression of natalizumab (Tysabri) in participants with relapsing remitting multiple sclerosis (RRMS) in a clinical practice setting.
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
- BIOLOGICAL
-
natalizumab
Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Director · Biogen
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-11-30
- Primary Completion
- 2017-12-31
- Completion
- 2017-12-31
Countries
- Ireland
Study Locations
More Related Trials
-
Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients
NCT01658384 ·Status: COMPLETED
-
TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World
NCT00483847 ·Status: COMPLETED
-
TYSABRI Global Observational Program in Safety
NCT00477113 ·Status: COMPLETED
-
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
NCT01071512 ·Status: COMPLETED ·Phase: NA
-
Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects
NCT00292253 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
NCT00937677 ·Status: COMPLETED
-
A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments
NCT06127095 ·Status: COMPLETED
-
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
NCT00536120 ·Status: COMPLETED ·Phase: PHASE4
-
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
NCT03399981 ·Status: COMPLETED
-
Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension
NCT02383550 ·Status: COMPLETED
-
Evaluation of Natalizumab for thE Relief of MS Associated FatiGue
NCT00464074 ·Status: COMPLETED
-
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05925049 ·Status: ACTIVE_NOT_RECRUITING
-
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01440101 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
COMparison Between All immunoTherapies for Multiple Sclerosis.
NCT03193866 ·Status: COMPLETED
-
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
NCT01706107 ·Status: TERMINATED
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
NCT01585766 ·Status: COMPLETED ·Phase: PHASE1
-
Examining Effects of Tysabri on Cognitive Fatigue Using fMRI
NCT04565431 ·Status: RECRUITING
-
Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis
NCT04777539 ·Status: COMPLETED
-
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS
NCT00884481 ·Status: COMPLETED
-
Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design
NCT01945359 ·Status: COMPLETED
-
Natalizumab Re-Initiation of Dosing
NCT00306592 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT02142205 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
NCT01455220 ·Status: COMPLETED ·Phase: NA
-
A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study
NCT01036165 ·Status: COMPLETED ·Phase: PHASE3